Patents. The lawsuit was filed beneath the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the courtroom, whichever occurs sooner, subject to any other exclusivities.S. Product sales of approximately $123 million, relating to IMS Health data.. Actavis documents ANDA to advertise Budesonide Extended-release Tablets Actavis plc today confirmed that it offers filed an Abbreviated New Drug Application with the U.S. Food and Medication Administration seeking acceptance to market Budesonide Extended-release Tablets, 9 mg. Cosmo Technologies Small and Santarus, Inc.And, over the last several weeks, we have identified areas where we can make substantial cuts. In fact, what we’ve been in a position to do is to provide to the home Republicans a spending budget framework that would cut the same amount of spending as Speaker Boehner and Chairman Rogers originally proposed.’ In response to a reporter’s query on the status of the budget negotiations, the elected president conveyed a belief that his administration is meeting the House leadership half-way. He proceeded to go on to convey, ‘But what we’re not really ready to do is venture out and say that – we’re going to cut medical analysis.